DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07316816

RecruitingPhase NA

Stanford Pediatric Healthy Weight Index

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

120

estimated

Study population

Bariatric Surgery Candidate, Obesity / overweight

Key I/E criterion

—

Primary endpoints

•BMI•Body weight, absolute change (kg)•Fasting glucose, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07316816
Org study ID81022

Timeline

Milestones

Study first posted2026-01-05actual
Study start2026-01-05estimated
Last update posted2026-01-05actual
Primary completion2030-12estimated (month precision)
Study completion2030-12estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Bariatric Surgery CandidateObesity / overweight

Eligibility

Who can enroll

Minimum age10 Years
Maximum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Class 2 and 3 obesity
•Patient in the Adolescent Bariatric Program at Stanford Children's that is eligible for either laparoscopic sleeve gastrectomy or GLP1 Receptor Agonist Therapy
•Willingness to wear a CGM and physiological monitor for the duration of the study.

Exclusion criteria

•Hypothalamic and syndromic obesity
•BMI > 55
•Plan to undergo bariatric surgical procedure other than sleeve gastrectomy
•Prior bariatric surgical procedure
•Active GLP treatment (within past 3 months)
•Unable to read, understand, or complete the informed consent in English or Spanish

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Weight & body composition
2
MASH / liver
1
Cardiometabolic biomarkers
1
Other clinical outcomes
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Percent Reduction in BMI

Time frame:baseline through study completion, an average of 4 months

percent change from baseline, improvement

Primary/protocol endpoint

Body Weight

Time frame:baseline through study completion, an average of 4 months

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

Fasting Glucose

Time frame:baseline through study completion, an average of 4 months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Primary/protocol endpoint

Fasting Insulin

Time frame:baseline through study completion, an average of 4 months

change from baseline, improvement

Primary/protocol endpoint

HbA1c

Time frame:baseline through study completion, an average of 4 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

1 endpoint
Primary/protocol endpoint/low confidence

Liver Enzymes

Time frame:baseline through study completion, an average of 4 months

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint/low confidence

Lipid Panel

Time frame:baseline through study completion, an average of 4 months

change from baseline, improvement

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

Obesity-related Comorbidities

Time frame:baseline through study completion, an average of 4 months

categorical status, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.